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1. Introduction 
Cardiovascular disease is the major cause of death in persons with type 1 diabetes (Libby et 
al., 2005). Dyslipidemia has been shown to be a significant coronary heart disease risk factor 
in type 1 diabetes (Soedamah-Muthu et al., 2004; Grauslund et al., 2010). Thus, it seems 
important to pay attention to lipid abnormalities, in patients with type 1 diabetes, in order to 
reduce cardiovascular disease in this population. 
Patients with type 1 diabetes show lipid disorders, mostly qualitative abnormalities of 
lipoproteins, which may promote atherogenesis. The pathophysiology of these lipid 
abnormalities is not totally explained, but hyperglycemia and peripheral hyperinsulinemia, 
due to the subcutaneous route of insulin administration, are likely to play a role. After a 
brief review of lipoprotein metabolism and some information on the role of insulin on lipid 
metabolism, quantitative abnormalities then qualitative abnormalities of lipoproteins, in 
type 1 diabetes, will be discussed. 
2. Brief review of lipoprotein metabolism  
Lipoproteins, which transport non-water soluble cholesterol and triglycerides in plasma, are 
spherical particles composed of a central core of non-polar lipids (cholesterol esters, 
triglycerides) and a surface monolayer of phospholipids, free cholesterol and 
apolipoproteins. Lipoproteins are generally classified according to their density as 
chylomicron, Very Low Density Lipoprotein (VLDL), Intermediate Density Lipoprotein 
(IDL), Low Density Lipoprotein (LDL) and High Density Lipoprotein (HDL). An overview 
of lipoprotein metabolism is shown in Figure 1. 
2.1 Chylomicrons 
Chylomicrons, the largest lipoprotein particles, are responsible for the transport of dietary 
triglycerides and cholesterol. Chylomicrons are composed of triglycerides (85-90%), 
cholesterol esters, phospholipids and apolipoproteins (mainly apoB48 but also apoA-I and 
apoA-IV). The formation of chylomicrons takes place in the enterocytes, and the process 
associating the lipid components (triglycerides, cholesterol esters, phospholipids) and the 
apoB48 is performed by the MTP (Microsomal Tranfer Protein). Chylomicrons are secreted 
into the lymphatic circulation before entering the bloodstream. In plasma, triglycerides of 
chylomicrons are hydrolyzed by the lipoprotein lipase leading to the formation of smaller, 
triglyceride-poorer particles known as chylomicron-remnants. Chylomicron-remnants are 
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cleared by the liver through LDL B/E receptor or LRP receptor (LDL-receptor related 
protein). 
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VLDL: Very Low Density Lipoprotein; IDL: Intermediate Density Lipoprotein, LDL: Low Density 
Lipoprotein; HDL: High Density Lipoprotein; LPL: LipoProtein Lipase; HL: Hepatic Lipase; CETP: 
Cholesteryl Ester Transfer Protein; LCAT: Lecithin-Cholesterol Acyl Transferase; FFA: Free Fatty Acids ; 
B/E rec.: B/E receptor (LDL receptor); TG: Triglycerides; CE: Cholesterol Esters; ABCA1: ATP Binding 
Cassette A1 transporter. 
Fig. 1. Human lipoprotein metabolism.  
2.2 VLDLs and IDLs 
VLDL particles, which are secreted by the liver, consist of endogenous triglycerides (55% to 
65%), cholesterol, phospholipids and apolipoproteins (apoB100 as well as apoCs and apoE). 
In the hepatocyte, the formation of VLDL occurs in two major steps. In the first step, which 
takes place in the rough endoplasmic reticulum, apoB is co-translationally and post-
translationally lipidated by the MTP (Microsomal Tranfer Protein). MTP transfers lipids 
(mainly triglycerides but also cholesterol esters and phospholipids) to apoB. This first step 
leads to the formation of pre-VLDL (Olofsson et al., 2000). In the second step, pre-VLDL is 
converted to VLDL in the smooth membrane compartment. This step is driven by ADP 
ribosylation factor-1 (ARF-1) and its activation of phospholipase D, needed for the 
formation of VLDL from pre-VLDL (Olofsson , 2000). 
In plasma, triglycerides of VLDLs are hydrolyzed by the lipoprotein lipase. As VLDLs 
become progressively depleted in triglycerides, a portion of the surface including 
phospholipids and apolipoproteins C and E is transferred to HDLs. This metabolic cascade 
leads to the formation of IDL particles, which are either cleared by the liver through LDL 
B/E receptor or further metabolized to form LDLs. The enzyme, hepatic lipase, which has 
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both triglyceride lipase and phospholipase activities, is involved in this metabolic process 
generating LDL particles from IDLs. 
2.3 LDLs 
LDL is the final product of the VLDL-IDL-LDL cascade. LDL is the main cholesterol-bearing 
lipoprotein in plasma. Each LDL particle contains one molecule of apoB100, which plays an 
important role in LDL metabolism, particularly recognition of its dedicated LDL B/E 
receptor. Clearance of LDL is mediated by the LDL B/E receptor. Seventy percent of LDL 
B/E receptors are located on hepatic cells and 30% on the other cells of the body.  
2.4 HDLs 
HDL particles are secreted by the hepatocytes as small lipid-poor lipoproteins, containing 
mostly apoA-I, which receive, in the circulation, phospholipids, apoCs and apoE from 
chylomicrons and VLDLs. Nascent or lipid-poor HDLs get from peripheral cells free 
cholesterol and phospholipids through ABCA1 transporter (ATP Binding Cassette A1 
transporter), allowing the transport of free cholesterol and phospholipids from the cell 
cytoplasm into the HDL particles (Oram & Lawn, 2001). Within HDL particles, free 
cholesterol is esterified by LCAT (Lecithin Cholesterol AcylTransferase) leading to the 
formation of HDL3 particles. The fusion of 2 HDL3 particles, which is promoted by PLTP 
(PhosphoLipid Transfer Protein), leads to the formation of one larger size HDL2 particle. HDL2 
lipoproteins, rich in cholesterol ester, are degraded by the hepatic lipase and the endothelial 
lipase, leading to the formation of HDL remnant particles that are cleared by the liver after 
recognition by SR-B1 receptor (Scavenger Receptor class B type 1) (Jian et al., 1998). 
2.5 Lipid transfer proteins 
Lipoprotein metabolism is largely influenced by lipid transfer proteins. Among these, two 
play an important role: CETP (Cholesteryl Ester Transfer Protein) and PLTP (PhosphoLipid 
Transfer Protein). CETP facilitates the transfer of triglycerides from triglyceride-rich 
lipoproteins (mainly VLDLs) toward HDLs and LDLs and the reciprocal transfer of 
cholesteryl esters from HDLs and LDLs toward VLDLs (Lagrost, 1994). PLTP facilitates the 
transfer of phospholipids and -tocopherol between lipoproteins. PLTP is also involved in 
the formation of HDL2 lipoproteins from HDL3 particles (Lagrost et al., 1998). Any 
modification of CETP or PLTP activities is likely to promote significant qualitative 
abnormalities of lipoproteins. 
3. Insulin and lipoprotein metabolism   
Insulin plays a central role in the regulation of lipid metabolism (Vergès, 2001). The main 
sites of action of insulin on lipoprotein metabolism are shown in Figure 2. 
In adipose tissue, insulin inhibits the hormone-sensitive lipase. Thus, insulin has an anti-
lipolytic action, promoting storage of triglycerides in the adipocytes and reducing release of 
free fatty acids from adipose tissue in the circulation. 
Insulin inhibits VLDL production from the liver. In normal subjects, it has been shown that 
insulin induces a 67% decrease of VLDL-triglyceride production and a 52% decrease of 
VLDL-apoB production (Lewis et al., 1993; Malmström et al., 1998). Insulin reduces VLDL 
production by diminishing circulating free fatty acids (due to its antilipolytic effect), which 
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are substrates for VLDL, but also by a direct inhibitory effect in the hepatocyte (Malmström 
et al., 1998). Insulin is a potent activator of lipoprotein lipase (LPL), promoting the 
catabolism of triglyceride-rich lipoproteins and reducing, as a consequence, plasma 
triglyceride level. Insulin not only enhances LPL activity (Brunzell et al., 1998), but has also 
a direct positive effect on LPL gene, promoting LPL synthesis (Fried etal., 1993). Insulin 
promotes the clearance of LDL, by increasing LDL B/E receptor expression and activity 
(Chait et al., 1979, Mazzone et al., 1984). 
Insulin acts also on HDL metabolism by activating LCAT and hepatic lipase activities 
(Ruotolo et al., 1994). 
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VLDL: Very Low Density Lipoprotein; IDL: Intermediate Density Lipoprotein, LDL: Low Density 
Lipoprotein; HDL: High Density Lipoprotein; LPL: LipoProtein Lipase; HL: Hepatic Lipase; CETP: 
Cholesteryl Ester Transfer Protein; LCAT: Lecithin-Cholesterol Acyl Transferase; FFA: Free Fatty Acids ; 
B/E rec.: receptor B/E (LDL receptor); TG: Triglycerides; CE: Cholesterol Esters. 1: insulin inhibits 
hormone-sensitive lipase. 2 : insulin activates LipoProtein Lipase (LPL). 3: insulin inhibits hepatic VLDL 
production. 4: insulin increases LDL B/E receptor expression. 5: insulin activates LCAT. 6: insulin 
activates Hepatic Lipase (HL). 
Fig. 2. Main effects of insulin on lipoprotein metabolism.  
4. Quantitative lipid abnormalities in type 1 diabetes 
4.1 Untreated (diabetic ketoacidosis) type 1 diabetes  
In type 1 diabetic patients with diabetic ketoacidosis, quantitative lipid abnormalities are 
observed, due to insulin deficiency. 
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Triglyceride-rich lipoproteins (chylomicrons, VLDLs) are increased leading to 
hypertriglyceridemia. This is mainly due to decreased lipoprotein lipase activity (Vergès, 
2001; Dullaart, 1995). Diabetic ketoacidosis is a situation of severe insulin deficiency with 
reduced lipoprotein lipase activity as a consequence, because insulin usually stimulates its 
activity. Decreased lipoprotein lipase activity leads to profound reduction of triglyceride-
rich lipoprotein catabolism (Taskinen, 1987). In this condition of severe insulin deficiency, 
reduced catabolism of triglyceride-rich lipoproteins is, by far, the main factor involved in 
hypertriglyceridemia. This hypertriglyceridemia resolves rapidly after well titrated insulin 
therapy (Weidman et al., 1982). 
LDL-cholesterol is decreased during diabetic ketoacidosis (Weidman et al., 1982). This fall in 
plasma LDL-cholesterol level is the direct consequence of the reduction of triglyceride-rich 
lipoprotein catabolism, due to decreased lipoprotein lipase activity (see above). 
 In diabetic ketoacidosis, HDL-cholesterol level is significantly decreased (Weidman et al., 
1982). This is a consequence of hypertrigliceridemia observed in this condition. Indeed, the 
augmented level of plasma triglyceride-rich lipoproteins drives, through CETP, the transfer 
of triglycerides from triglyceride-rich lipoproteins to HDLs leading to the formation of 
triglyceride-rich HDL particles. HDLs enriched in triglycerides become very good substrate 
for hepatic lipase, leading to increase their catabolism and, thus, to decrease plasma HDL-
cholesterol level. This low HDL-cholesterol condition resolves rapidly after well titrated 
insulin therapy (Weidman et al., 1982). 
4.2 Treated type 1 diabetes 
Patients with treated type 1 diabetes may show quantitative lipid disorders. In a prospective 
study performed in 895 young subjects with type 1 diabetes, 20.1% had plasma triglycerides 
above 1.7 mmol/l, 9.6% had LDL-cholesterol above 3.4 mmol/l and 25.9% had non-HDL 
cholesterol above 3.4 mmol/l (Marcovecchio  et al., 2009). It has been shown that abnormal 
lipid levels, in type 1 diabetes, predict worse cardiovascular outcomes (Soedamah-Muthu et 
al., 2004). HbA1c has been shown to be independently correlated with LDL-cholesterol, non-
HDL cholesterol and triglyceride levels, indicating that these disorders were mostly 
observed in patients with poor glycemic control (Marcovecchio  et al., 2009). In a British 
follow-up study of 229 children with type 1 diabetes, LDL cholesterol and non-HDL 
cholesterol values increased with duration of diabetes (Edge et al., 2008). In that study, total 
cholesterol, triglycerides and non-HDL cholesterol were positively correlated with HbA1c 
and around 10% of the patients had lipid values outside recommendations (Edge et al., 
2008). In a large study performed in 29 979 patients with type 1 diabetes, multivariate 
analyses showed a significant positive association between HbA1c and total cholesterol 
(p<0.0001), LDL cholesterol (p<0.0001) and a significant negative association between 
HbA1c and HDL cholesterol (p<0.0001) (Schwab et al., 2009).  In the Diabetes Control and 
Complications Trial (DCCT), HbA1c correlated positively with total cholesterol, LDL-
cholesterol and triglycerides at baseline (The DCCT Research Group, 1992).  Data from the 
Coronary Artery Calcification in type 1 diabetes (CACTI) study, which examined 652 
patients with type 1 diabetes, have shown, in patients not using hypolipidemic agents, that a 
higher HbA1c was associated with significantly higher levels of total cholesterol, 
triglycerides, LDL cholesterol and non-HDL cholesterol (Maahs et al., 2010). In that study, 
1% change in HbA1c was associated with an increase of 0.101 mmol/l (4 mg/dl) for total 
cholesterol, of 0.052 mmol/l (4.5 mg/dl) for triglycerides, of 0.103 mmol/l (4 mg/dl) for 
LDL cholesterol and of 0.129 mmol/l (5 mg/dl) for non-HDL cholesterol (Maahs et al., 
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2010). In a recent study, performed in 512 young patients with type 1 diabetes and in 188 
healthy age-matched controls, patients with suboptimal control (HbA1c  7.5%) had much 
more lipid quantitative disorders than patients with optimal control (HbA1c<7.5%) (Guy et 
al., 2009). All these data suggest that quantitative lipid abnormalities are more frequent, 
when type 1 diabetes is not well controlled. 
In addition, some patients with type 1 diabetes may have insulin resistance, in situation of 
abdominal obesity and/or family history of type 2 diabetes. Such patients have been shown 
to have greater dyslipidemia (Purnell et al., 2003). In a recent study performed in 60 young 
type 1 diabetic patients and 40 adults with type 1 diabetes, it has been shown, using 
hyperinsulinemic clamp studies, that lower glucose infusion (more insulin resistance) was 
associated with lower levels of HDL cholesterol in youths with type 1 diabetes and with 
higher levels of triglycerides and higher triglyceride/HDL ratio in both youths and adults 
(Maahs et al., 2011). These data indicate that insulin resistance may be an additional factor 
that could induce quantitative lipid abnormities in some type 1 diabetic patients with a 
background of insulin resistance (abdominal obesity, family history of type 2 diabetes). In 
this chapter we will consider only the typical situation of type 1 diabetes without insulin 
resistance. 
4.2.1 Treated type 1 diabetes with poor or suboptimal glycemic control  
In case of poor or suboptimal control, patients with type 1 diabetes may show increased 
plasma triglyceride levels (Dullaart,1995). This hypertriglyceridemia is due to increased 
production of VLDL, promoted by elevated circulating free fatty acids secondary to the 
relative insulin deficiency (Nikkilä & Kekki, 1973). 
Type 1 diabetic patients with poor or suboptimal glycemic control show increased LDL-
cholesterol levels as compared to non–diabetic individuals and type 1 diabetic patients with 
optimal glycemic control (Dullaart, 1995; Guy et al., 2009). Indeed, in this condition, VLDL 
production is increased (see above), when catabolism of triglyceride-rich lipoproteins is not 
importantly decreased, which leads to increase LDL production (Dullaart, 1995). 
4.2.2 Treated type 1 diabetes with optimal glycemic control  
In well controlled type 1 diabetes, the lipid profile is totally different than in poorly 
controlled type 1 diabetes (Dullaart, 1995; Nikkilä & Kekki, 1973). 
Plasma triglycerides are normal or slightly decreased (Dullaart, 1995; Nikkilä & Kekki, 
1973). This slight decrease in plasma triglycerides may be observed with intense insulin 
therapy because of increased down control of VLDL production by augmented plasma 
insulin levels as a consequence of the subcutaneous route of insulin delivery (Dashti & 
Wolfbauer, 1987; Taskinen, 1992). Furthermore, in patients with well controlled type 1 
diabetes, peripheral hyperinsulinemia has been shown to be associated with increased 
lipoprotein lipase activity that could be an additional factor responsible for decreased 
plasma triglycerides (Nikkilä  et al., 1977). 
Plasma LDL-cholesterol level is normal or slightly decreased (Winocour et al., 1986). This 
slight decrease in plasma LDL-cholesterol may be observed with intense insulin therapy as a 
consequence of decreased VLDL production by peripheral hyperinsulinemia (see above). 
Plasma HDL-cholesterol level is normal or slightly increased in well controlled type 1 
diabetic patients (Dullaart, 1995). Some studies have shown an increase in HDL subfraction 
2 (Eckel et al., 1981; Kahri et al., 1993), when others have found an increase in HDL 
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subfraction 3 (Winocour et al., 1986). It has also been reported that elevation of HDL in type 
1 diabetic patients with good glycemic control was caused by an increase of HDL particles 
containing only apoA-I (LpA-I) (Kahri et al., 1993). This increase in plasma HDL-cholesterol 
could be the consequence of the elevated Lipoprotein Lipase/Hepatic Lipase ratio that is 
observed in patients with well controlled type 1 diabetes (increased Lipoprotein Lipase 
activity and normal Hepatic Lipase activity) (Kahri et al., 1993). The increased Lipoprotein 
Lipase activity observed in these patients is likely to be due to peripheral hyperinsulinemia 
as a consequence of the subcutaneous route of insulin administration (Kahri et al., 1993).  
4.2.3 Subcutaneous insulin therapy versus intraperitoneal insulin therapy 
Intensive subcutaneous insulin therapy results in normalization of plasma glucose, but at 
the expense of peripheral hyperinsulinemia, which is likely to modify lipoprotein 
metabolism (as discussed above). Implantable insulin pumps with intraperitoneal insulin 
administration mimic the physiologic route of insulin delivery and are likely to restore the 
normal portal-peripheral insulin gradient. For this reason, several studies have been 
performed to analyze the modification of lipoprotein metabolism after replacement of 
subcutaneous insulin therapy by intraperitoneal insulin therapy. Plasma triglycerides have 
been found increased in one study (Selam et al., 1989) and unchanged in three other studies 
(Bagdade & Dunn, 1996; Ruotolo et al., 1994; Duvillard et al., 2005). Total cholesterol and 
apoB were found unchanged (Bagdade & Dunn, 1996; Ruotolo et al., 1994; Duvillard et al., 
2005). HDL-cholesterol has been found decreased (Selam et al., 1989) or not modified 
(Bagdade & Dunn, 1996; Ruotolo et al., 1994; Duvillard et al., 2007). The discrepancies of 
these studies that may be due to confounding factors such as degree of glycemic control and 
peripheral insulin levels during subcutaneous insulin therapy. Further studies are needed to 
clearly evaluate the effect of intraperitoneal insulin administration on lipoprotein 
metabolism. 
4.2.4 Type 1 diabetes with nephropathy 
In type 1 diabetic patients with nephropathy and overt albuminuria, elevated plasma 
levels of total cholesterol, triglycerides and LDL-cholesterol are observed whereas HDL-
cholesterol is decreased due to a fall in HDL2 (Dullaart ,1995; Taskinen, 1992; Jensen et al., 
1987). In the EURODIAB IDDM Complications study, macroalbuminuria was associated 
with significantly increased plasma triglycerides, cholesterol, LDL-cholesterol and 
LDL/HDL ratio in both sexes and decreased HDL-cholesterol in women (Mattock et al., 
2001). 
Some quantitative lipid modifications are also observed in type 1 diabetic patients with 
microalbuminuria. Microalbuminuric patients compared with normoalbuminuric patients 
show increased plasma apoB (Jones et al., 1989, Dullaart et al, 1989a; Jay et al., 1991), LDL 
cholesterol (Jones et al., 1989, Dullaart et al, 1989a) and apoB/apoA1 ratio (Dullaart et al, 
1989a; Jay et al., 1991). A positive correlation has been found between urinary albumin 
excretion rate and plasma apoB and apoB/apoA1 ratio (Dullaart et al, 1989a). In the 
EURODIAB IDDM Complications study, microalbuminuria was associated with increased 
plasma triglycerides (Mattock et al., 2001). In a prospective study performed in 895 young 
subjects with type 1 diabetes, total cholesterol and non-HDL cholesterol were independently 
related to longitudinal changes in albumin-to-creatinine ratio (Marcovecchio et al., 2009). 
The mechanisms responsible for these lipoprotein abnormalities in type 1 diabetic patients 
with microalbuminuria remain unclear. 
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Moreover, serum lipids have been shown to be associated with the progression of 
nephropathy in type 1 diabetes. In a prospective study performed in 152 patients with type 
1 diabetes followed for 8-9 years, LDL-cholesterol was an independent factor associated 
with progression of nephropathy (Thomas et al., 2006). 
5. Qualitative lipid abnormalities in type 1 diabetes 
Several qualitative abnormalities of lipoproteins are observed in patients with type 1 
diabetes, even in those with good metabolic control, who do not have significant 
quantitative lipid changes. These qualitative lipid abnormalities are not totally reversed by 
optimal glycemic control and are likely to be atherogenic. 
5.1 VLDLs  
VLDLs from patients with type 1 diabetes are frequently enriched in esterified cholesterol at 
the expense of triglycerides leading to an increased VLDL cholesterol/triglyceride ratio 
(Rivellese et al., 1988; Bagdade et al., 1991a). It has been suggested that this compositional 
changes may be due to increased cholesteryl ester transfer between lipoproteins (Bagdade et 
al., 1991a). It has been shown that the VLDL cholesterol/triglyceride ratio was significantly 
reduced with intraperitoneal insulin therapy (Dunn, 1992).  Furthermore, the free 
cholesterol /lecithin ratio within the peripheral layer of VLDL particles is increased 
(Dullaart, 1995; Bagdade et al., 1991a). Such increase in the free cholesterol /lecithin ratio 
within the peripheral layer of lipoproteins has been shown to raise the risk for 
cardiovascular events possibly by reducing fluidity and stability of lipoproteins (Kuksis, 
1982). Moreover, VLDLs from patients with type 1 diabetes have been shown, in vitro, to 
induce abnormal response of cellular cholesterol metabolism in human macrophages (Klein 
et al., 1989). 
5.2 LDLs  
In patients with type 1 diabetes, LDLs are often enriched in triglycerides and increased 
number of small dense LDL particles is observed (Guy et al., 2009; Lahdenperä et al., 1994; 
James & Pometta, 1990; Skyrme-Jones et al., 2000). In a study performed in 2657 patients 
with type 1 diabetes, it has been shown that dense LDL increased with HbA1c with buoyant 
LDL shifting toward dense LDL for HbA1c values above 8% (Albers et al., 2008). It has been 
shown that the presence of small dense LDL particles is associated with increased 
cardiovascular risk (Austin et al., 1990). Many data indicate that small dense LDL particles 
have atherogenic properties. Indeed, small dense LDL particles have reduced affinity for the 
LDL B/E receptor and are preferentially taken up by macrophages, through the scavenger 
receptor, leading to the formation of foam cells. Small dense LDL particles have higher 
affinity for intimal proteoglycans than large LDL particles which may favor the penetration 
of LDL particles into the arterial wall (Chapman et al., 1998). It has been shown that subjects 
with small dense LDL particles show an impaired response to endothelium dependent 
vasodilator acetylcholine (Vakkilainen et al., 2000). Moreover, small dense LDL particles 
show an increased susceptibility to oxidation (Tribble et al., 1992). A reduction of the 
proportion of small dense LDL particles has been reported after optimization of glycemic 
control in patients with type 1 diabetes (Caixàs et al., 1997). 
The free cholesterol /lecithin ratio within the peripheral layer of LDL particles is increased 
(Dullaart, 1995; Bagdade et al., 1991a). In patients with type 1 diabetes, glycation of ApoB 
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occurs within LDL in parallel with plasma hyperglycemia. It has been shown that apoB 
glycation reduces significantly LDL binding to the B/E receptor even when apoB glycation 
is moderate (Witztum et al., 1982; Steinbrecher et al, 1984). Furthermore, glycated LDLs are 
preferentialy taken up by macrophages through the scavenger receptor, leading to the 
formation of foam cells in the arterial wall. In patients with type 1 diabetes, advanced 
glycation end products-modified LDL have been shown to be positively associated with 
increased intima media thickness (IMT) (Lopes-Virella et al., 2011). 
Moreover, patients with type 1 diabetes may show an increased oxidation of LDL which is 
promoted by glycemic excursions (de Castro et al., 2005). Increased urinary excretion of 
malondialdehyde, reflecting enhanced lipid peroxidation, has been reported in patients with 
type 1 diabetes (Hoeldtke et al., 2009). Oxidative modification of LDL results in rapid uptake 
by macrophages, leading to foam cell formation. Oxidized LDLs produce chemotactic effects 
on monocytes by increasing the synthesis of adhesion molecules, such as ICAM-1 
(intercellular adhesion Molecule 1) by endothelial cells. Oxidized LDLs stimulate the 
formation by macrophages of cytokines, such as TNF or IL1, which amplify the 
inflammatory atherosclerotic process.  It has recently been shown that oxidized LDL 
particles were significantly associated with progression and increased levels of IMT in type 
1 diabetes (de Castro et al., 2005). 
5.3 HDLs 
HDL particles from patients with type 1 diabetes are often enriched in triglycerides 
(Dullaart, 1995; Bagdade et al., 1991a). This modification has been attributed to increased 
cholesteryl ester transfer between lipoproteins (Bagdade et al., 1991a). In HDL particles from 
patients with type 1 diabetes, sphingomyelin/lecithin ratio within the peripheral layer is 
augmented, which may increase HDL rigidity (Bagdade & Subbaiah, 1989). These 
alterations are not totally reversed after achievement of optimal glycemic control (Bagdade 
et al., 1991b). ApoA-I within HDL is glycated in patients with type 1 diabetes, which may 
impair the HDL-mediated reverse cholesterol pathway. Indeed, it has been shown that HDL 
particles containing glycated apoA-I were less effective to promote cholesterol efflux from 
the cells (Fievet et al., 1992).  
In addition to their role in the reverse cholesterol pathway, HDLs have anti-oxidative, anti-
inflammatory, anti-thrombotic and vasorelaxant properties, potentially anti-atherogenic 
(Link et al., 2007). Some of these properties have been shown to be reduced in patients with 
type 1 diabetes. Indeed, a significant reduction of the activity of paraoxonase, an anti-
oxidative enzyme associated with HDLs, is observed in patients with type 1 diabetes (Boemi 
et al., 2001; Ferretti et al., 2004). As a consequence, HDLs from patients with type 1 diabetes 
protect less efficiently erythrocyte membranes and LDL particles against oxidative damage 
than HDLs from normal individuals (Boemi et al., 2001; Ferretti et al., 2004). Furthermore, 
using rabbit aorta rings, it has been shown that HDL from patients with type 1 diabetes are 
no more able to prevent the endothelium dependent vasoconstriction induced by oxidized 
LDL, whereas HDL from normal individuals can prevent it (Perségol et al., 2007). 
5.4 Lipid transfer proteins 
In some studies, an increased cholesteryl ester transfer between lipoproteins (Bagdade et al., 
1991a; Bagdade et al., 1994) or an augmented activity of CETP (Colhoun et al., 2001) have 
been found in normolipidemic patients with type 1 diabetes. In some other studies, 
increased CETP activity has been reported only in type 1 diabetic patients that smoke or 
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those having microalbuminuria (Dullaart et al., 1989b; Dullaart et al., 1991). This augmented 
CETP activity may explain the increase in free cholesterol/ triglycerides ratio within VLDL 
and its decrease within HDL. Some studies have shown a positive correlation between CETP 
activity and hyperglycemia (Ritter & Bagdade, 1994; Chang et al., 2001). However, the main 
factor which is likely to be responsible for increased CETP activity, in type 1 diabetes, could 
be peripheral hyperinsulinemia secondary to the subcutaneous route of insulin 
administration. Indeed, peripheral hyperinsulinemia has been shown to be responsible for 
increased lipoprotein lipase activity in patients with type 1 diabetes (Nikkilä  et al., 1977) 
and it has been reported that lipoprotein lipase, in presence of VLDL, enhances CETP 
activity (Sammett & Tall,1985; Pruneta et al., 1999). Moreover, it has been shown, in patients 
with type 1 diabetes, that the increase in both lipoprotein lipase and CETP activities was 
abolished when insulin was administrated intraperitoneously with implantable insulin 
pumps, mimicking the physiologic portal route or after pancreatic graft (Bagdade et al., 
1994; Bagdade et al., 1996).  
Increased PLTP activity has been reported in patients with type 1 diabetes (Colhoun et al., 
2001). In this study, PLTP activity was positively correlated with CETP activity, LDL-
cholesterol and HDL-cholesterol (Colhoun et al., 2001). The reasons and consequences of 
this increased PLTP activity are not clear. 
6. Conclusion 
In conclusion, quantitative lipid abnormalities are observed in patients with poorly 
controlled type 1 diabetes (increased triglyceride and LDL-cholesterol levels) or with micro- 
or macroalbuminuria (increased triglycerides and LDL-cholesterol, decreased HDL-
cholesterol). Patient with optimally controlled type 1 diabetes show normal or slightly 
decreased triglycerides and LDL-cholesterol levels and sometimes increased HDL-
cholesterol levels. Qualitative abnormalities of lipoproteins are observed in patients with 
type 1 diabetes, even in good glycemic control. These abnormalities are not fully explained 
by hyperglycemia and may partly be due to peripheral hyperinsulinemia associated with 
the subcutaneous route of insulin administration. The exact consequences of these 
qualitative lipid changes on the development of cardiovascular disease in type 1 diabetes 
are still unknown.  
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